Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and Medroxyprogesterone Acetate in Endometrial Cancer
NCT03018249Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of entinostat in endometrial endometrioid adenocarcinoma (EEA) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Mean Post-treatment Tumor Progesterone Receptor Histology Score at 3 weeks. Started Oct 2017; status: completed.
02
Drugs
entinostat
03
Conditions
endometrial endometrioid adenocarcinoma (EEA)
Beyond the preview
Go deeper on NCT03018249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018249.